Reliance Chemotex Industries Ltd has approved an amended Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information (UPSI) to strengthen compliance with SEBI regulations. The board approved the updated code at its meeting held on May 29, 2026, pursuant to Regulation 8(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. The amendment ensures that the company maintains uniformity, transparency, and fairness in its dealings with all stakeholders while preventing the misuse of sensitive information.

The revised code mandates that the company ensure prompt disclosure of UPSI to the stock exchanges where its securities are listed. It emphasizes that information must be universally disseminated to avoid selective disclosure, and once submitted to the exchange, the information is deemed generally available and no longer treated as UPSI. The Company Secretary & Compliance Officer serves as the Chief Investor Relation Officer responsible for the dissemination of information and handling UPSI disclosures.

Principles of Fair Disclosure

The code outlines specific principles to prevent insider trading and ensure market integrity. Key measures include:

• Prompt dissemination of any UPSI disclosed selectively or inadvertently.
• Providing fair responses to queries on news reports and market rumors from regulatory authorities.
• Ensuring information shared with analysts and research personnel is not UPSI.
• Maintaining transcripts or records of proceedings from analyst meetings on the official website.

The company is required to handle all UPSI on a "need to know" basis only. A structured digital database will be maintained to record details of individuals or entities with whom UPSI is shared for legitimate purposes, including their Permanent Account Number or other legal identifiers. This database will feature internal controls such as time stamping to prevent tampering.

Version Control

The following table details the approval history of the code:

The policy defines "legitimate purpose" for sharing UPSI as interactions with partners, collaborators, lenders, or advisors in the ordinary course of business, provided it is not intended to circumvent regulations. Any person receiving UPSI for a legitimate purpose is considered an "Insider" and must be bound by non-disclosure agreements outlining their duties and liabilities.

Reliance Chemotex Industries Limited reported a 30.1% year-on-year increase in net profit for the financial year ended March 31, 2026, reaching ₹526.15 lakh. The board of directors approved the audited financial results for the quarter and year ended March 31, 2026, and recommended a final dividend of 5%, or ₹0.50 per equity share, subject to shareholder approval. The financial results were published in the Financial Express and Jai Rajasthan newspapers on May 30, 2026.

Financial Performance

For the full year, revenue from operations rose to ₹36,200.58 lakh from ₹35,859.78 lakh in the previous year. Total income for FY26 stood at ₹36,583.52 lakh. The company’s profit before tax for the year increased to ₹484.05 lakh from ₹365.69 lakh in FY25. For the quarter ended March 31, 2026, net profit was recorded at ₹174.59 lakh, compared to ₹184.02 lakh in the corresponding period of the previous year.

Dividend Recommendation

The board has recommended a final dividend of ₹0.50 per share on equity shares of face value ₹10 each for FY26. The total dividend payout aggregates to ₹37.72 lakh. The declaration is subject to the approval of shareholders.

Key Financial Metrics

Regulatory and Auditor Details

The statutory auditor, M/s. P K M B & Co, Chartered Accountants, issued an unmodified opinion on the audited standalone financial results. The trading window for designated persons and their immediate relatives will remain closed until May 31, 2026. The company operates a single reportable primary business segment in Yarn.